601A anti-VEGF Ab is under clinical development by Sunshine Guojian Pharmaceutical Shanghai and currently in Phase III for Branch Retinal Vein Occlusion. According to GlobalData, Phase III drugs for Branch Retinal Vein Occlusion have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how 601A anti-VEGF Ab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
601A anti-VEGF Ab overview
The drug candidate is under development for the treatment of age-related macular degeneration, diabetic macular edema, macular edema and branch retinal vein occlusion and pathologic myopiachoroid neovascularization. The therapeutic candidate is administered through intravitreal route. It is a class I monoclonal antibody targeting vascular endothelial growth factor (VEGF).
It was under development for diabetic retinopathy, retinal vein occlusion, non-small cell lung cancer and cervical cancer, choroidal neovascularization.
Sunshine Guojian Pharmaceutical Shanghai overview
Sunshine Guojian Pharmaceutical Shanghai (Sunshine Guojian Pharmaceutical), a subsidiary of 3SBio Inc, is a biopharmaceutical company. It develops antibodies and drugs. The company’s pipeline products include TNF- alpha is for the treatment of rheumatoid arthritis, spondylitis, psoriasis; IL-17A targets moderate to severe plaque psoriasis; IL-5 treats severe eosinophilic asthama; IL-4R for severe atopic dermatitis in adults, chronic sinusitis with nasal polyps; The 1B targets acute gouty arthritis; IL-33 for chronic obstructive pulmonary emphysema; HER2, PD1/ VEGF, PD-1 are for the treatment of solid tumors; CD20 targets non- hodgkin lymphoma; EGFR for metastic colorectal cancer; PD1/HER2 treats metastic breast cancer, gastric cancer; VEGF is for the treatment of neovascularization (wet) age related macular degeneration, diabetic macular edema, retinal vein occlusion, choroidal. Sunshine Guojian Pharmaceutical is headquartered in Shanghai, China.
For a complete picture of 601A anti-VEGF Ab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
